アラシ　ヒロユキ   Arashi Hiroyuki   嵐　弘之    所属   医学部 医学科（附属足立医療センター）    職種   教授
言語種別	日本語
発表タイトル	Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Using Drug-eluting Stents: A Multi-center Cohort Study
会議名	第79回日本循環器学会学術集会
主催者	日本循環器学会
学会区分	全国規模の学会
発表形式	口頭
講演区分	シンポジウム・ワークショップ パネル（公募）
発表者・共同発表者	◎山口淳一, 大槻尚男, 渡邉真広, 神島一帆, 嵐弘之, 重城健太郎, 本田淳, 藤井真也, 森文章, 田中博之, 太田吉実, 高木厚, 萩原誠久
発表年月日	2015/04/25
開催地 （都市, 国名）	大阪市
概要	The safety and efficacy of oral anticoagulation (OAC) in addition to dual antiplatelet therapy (DAPT) in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) using drug-eluting stent (DES) have not yet been fully evaluated in contemporary practice. A total of consecutive 450 patients with AF undergoing PCI during January 2010 to December 2012 were enrolled at 8 medical centers. Among them, 297 patients who underwent PCI using DES were examined. The incidence of major adverse cardiovascular events (MACE) and bleeding complication were evaluated. Median follow up period was 2.1±1.1 years. The mean age was 72.2±9.0, the percentage of male was 79%, diabetes was 49%, paroxysmal AF was 49% and renal dysfunction (eGFR<60ml/min/1.73m2) was 38%. The number of patients who took OAC + DAPT was 185(62%), who showed high CHA2DS2-Vasc (≥2) was 224(75%) and HAS-BLED (≥3) was 109(37%). Cumulative incidence of MACE and bleeding complication in each group during follow-up period were shown in table. The results of detailed analysis will be shown at the time of presentation.